ETAP-lab

Executive Summary

ETAP-lab is a French contract research organization (CRO) founded in 1991, specializing in preclinical pharmacology services for the pharmaceutical and agro-food industries. With expertise in in vitro and in vivo models across dermatology, neurology, neurovascular, cardiovascular, and neurodegenerative diseases, the company offers independent, scientific research support to drug developers. As a private, pre-clinical stage firm with no disclosed funding rounds, ETAP-lab has operated steadily for over three decades, positioning itself as a reliable partner in early-stage drug discovery. Its focus on niche therapeutic areas and long-standing market presence provide a stable foundation, though limited public information suggests a gradual growth trajectory rather than exponential expansion. The company's conviction score reflects its established but unremarkable profile in the competitive CRO landscape.

Upcoming Catalysts (preview)

• Q4 2026New service expansion in neurodegenerative disease models60% success
• Q2 2027Strategic partnership with a major pharmaceutical company40% success
• Q3 2026Renewal of ISO 9001 certification or equivalent quality accreditation90% success